{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:15:52Z","timestamp":1790036152363,"version":"4.0.1"},"reference-count":31,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Comprehensive real-world data on dose-adjusted EPOCH-R (DA-EPOCH-R) incorporating molecular prognostic stratification remain limited. We evaluated the long-term efficacy, safety, and prognostic determinants of DA-EPOCH-R in a multicenter Turkish cohort. Materials and Methods: This retrospective study included 140 patients with aggressive B-cell lymphoma (diffuse large B-cell lymphoma [DLBCL], n = 81; primary mediastinal B-cell lymphoma [PMBL], n = 39; other, n = 20) treated with DA-EPOCH-R at five academic centers (2015\u20132020). Molecular profiling included immunohistochemistry (MYC, BCL-2, BCL-6) and fluorescence in situ hybridization (FISH). Survival was estimated by Kaplan\u2013Meier analysis with Cox regression for prognostic factors. Results: At a median follow-up of 50.1 months, 5-year overall survival (OS) and event-free survival (EFS) rates were 71.3% and 66.3%, respectively (complete response rate: 68.6%). Molecular subtypes included double-expressor (DEL; n = 39), triple-expressor (TEL; n = 21), double-hit (DHL; n = 17), and triple-hit lymphoma (THL; n = 11). Five-year OS by IPI risk group ranged from 88.6% (low) to 49.4% (high) (p = 0.005). DEL status did not confer inferior OS (p = 0.738), whereas DHL and THL had markedly poor outcomes (p &lt; 0.001). In multivariate analysis, IPI \u2265 3 (HR 2.54; p = 0.007) and MYC FISH rearrangement (HR 3.62; p &lt; 0.001) independently predicted inferior OS. Grade 3\u20134 neutropenia occurred in 57.1%, with no grade 3\u20134 cardiotoxicity. Conclusions: DA-EPOCH-R provides favorable long-term outcomes in aggressive B-cell lymphomas. DEL status did not confer a survival disadvantage, an association that is hypothesis-generating and requires confirmation, as the present design cannot establish a causal mechanism. FISH-defined DHL\/THL remain associated with dismal outcomes, warranting novel therapeutic strategies.<\/jats:p>","DOI":"10.3390\/medicina62061117","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T16:25:16Z","timestamp":1780935916000},"page":"1117","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dose-Adjusted EPOCH-R in Aggressive B-Cell Lymphomas: Efficacy, Molecular Prognostic Factors, and Real-World Outcomes from a Multicenter Turkish Cohort\u2014A Turkish Oncology Group (TOG) Study"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4750-720X","authenticated-orcid":false,"given":"Mehmet Mutlu","family":"Kidi","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana 01250, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1366-5552","authenticated-orcid":false,"given":"Hatice","family":"Asoglu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana 01250, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8606-5601","authenticated-orcid":false,"given":"Metehan","family":"Soysal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana 01250, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tolga","family":"Koseci","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana 01250, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail Oguz","family":"Kara","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana 01250, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berksoy","family":"Sahin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana 01250, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4642-3693","authenticated-orcid":false,"given":"Semra","family":"Paydas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana 01250, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7538-9119","authenticated-orcid":false,"given":"Musa Bar\u0131\u015f","family":"Aykan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, G\u00fclhane Training and Research Hospital, Ankara 06010, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuri","family":"Karadurmus","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, G\u00fclhane Training and Research Hospital, Ankara 06010, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5733-439X","authenticated-orcid":false,"given":"Ibrahim","family":"Barista","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hacettepe University, Ankara 06230, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"Akin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hacettepe University, Ankara 06230, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1650-154X","authenticated-orcid":false,"given":"Fatih","family":"Kus","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hacettepe University, Ankara 06230, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meltem Olga","family":"Akay","sequence":"additional","affiliation":[{"name":"Department of Hematology, Koc University Hospital, Istanbul 34010, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Kalyon","sequence":"additional","affiliation":[{"name":"Department of Hematology, Koc University Hospital, Istanbul 34010, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Boga","sequence":"additional","affiliation":[{"name":"Department of Hematology, Baskent University Adana Dr. Turgut Noyan Hospital, Adana 01250, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Ozdogu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Baskent University Adana Dr. Turgut Noyan Hospital, Adana 01250, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8713-7613","authenticated-orcid":false,"given":"Ertugrul","family":"Bayram","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana 01250, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse Large B-Cell Lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from the International SCHOLAR-1 Study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of Induction Regimen and Stem Cell Transplantation on Outcomes in Double-Hit Lymphoma: A Multicenter Retrospective Analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated with Rituximab plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma","volume":"368","author":"Dunleavy","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.14951","article-title":"Outcomes of Adults and Children with Primary Mediastinal B-Cell Lymphoma Treated with Dose-Adjusted EPOCH-R","volume":"179","author":"Chen","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","article-title":"The Molecular Signature of Mediastinal Large B-Cell Lymphoma Differs from That of Other Diffuse Large B-Cell Lymphomas and Shares Features with Classical Hodgkin Lymphoma","volume":"102","author":"Savage","year":"2003","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/blood-2010-06-291328","article-title":"Clinically Significant Cardiac Disease in Patients with Hodgkin Lymphoma Treated with Mediastinal Irradiation","volume":"117","author":"Galper","year":"2011","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1182\/blood.V99.8.2685","article-title":"Dose-Adjusted EPOCH Chemotherapy for Untreated Large B-Cell Lymphomas: A Pharmacodynamic Approach with High Efficacy","volume":"99","author":"Wilson","year":"2002","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-Adjusted EPOCH-R Compared with R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project (1993). A Predictive Model for Aggressive Non-Hodgkin\u2019s Lymphoma. N. Engl. J. Med., 329, 987\u2013994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2017.76.5198","article-title":"Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials","volume":"36","author":"Maurer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone","volume":"30","author":"Green","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","article-title":"Dose-Adjusted EPOCH-R in Untreated Aggressive Diffuse Large B-Cell Lymphoma with MYC Rearrangement: A Prospective, Multicentre, Single-Arm Phase 2 Study","volume":"5","author":"Dunleavy","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1002\/cncr.31646","article-title":"Double Hit and Double Expressors in Lymphoma: Definition and Treatment","volume":"124","author":"Riedell","year":"2018","journal-title":"Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1007\/s00277-024-06067-2","article-title":"Real-World Outcomes of Diffuse Large B-Cell Lymphoma Treated with Frontline R-CHOP(-like) Regimens in an Asian Multi-Ethnic Population","volume":"103","author":"Lim","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.3324\/haematol.2022.281461","article-title":"Modern, Real-World Patterns of Care and Clinical Outcomes Among Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma with or without Double\/Triple-Hit Status in the United States","volume":"108","author":"Goyal","year":"2023","journal-title":"Haematologica"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e30620","DOI":"10.1097\/MD.0000000000030620","article-title":"DA-EPOCH-R Improves the Prognosis of Patients with Double-Expressor Lymphoma: A Single-Center Retrospective Study and Meta-Analysis","volume":"101","author":"Zhan","year":"2022","journal-title":"Medicine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00432-018-2771-9","article-title":"DA-EPOCH-R Improves the Outcome over That of R-CHOP Regimen for DLBCL Patients below 60 Years, GCB Phenotype, and Those with High-Risk IPI, but Not for Double Expressor Lymphoma","volume":"145","author":"Zhang","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/s41375-018-0320-9","article-title":"Dose-Adjusted EPOCH plus Rituximab Improves the Clinical Outcome of Young Patients Affected by Double Expressor Diffuse Large B-Cell Lymphoma","volume":"33","author":"Dodero","year":"2019","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3324\/haematol.2021.278638","article-title":"Dose-Adjusted EPOCH and Rituximab for the Treatment of Double Expressor and Double-Hit Diffuse Large B-Cell Lymphoma: Impact of TP53 Mutations on Clinical Outcome","volume":"107","author":"Dodero","year":"2022","journal-title":"Haematologica"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e947","DOI":"10.1016\/j.clml.2022.06.013","article-title":"R-CHOP vs. DA-EPOCH-R for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis","volume":"22","author":"Othman","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.18.01583","article-title":"Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma","volume":"37","author":"Ennishi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.2019002729","article-title":"International Prognostic Indices in Diffuse Large B-Cell Lymphoma: A Comparison of IPI, R-IPI, and NCCN-IPI","volume":"135","author":"Ruppert","year":"2020","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the Molecular Classification of Diffuse Large B-Cell Lymphoma by Immunohistochemistry Using a Tissue Microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/6\/1117\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T16:56:12Z","timestamp":1780937772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/6\/1117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["medicina62061117"],"URL":"https:\/\/doi.org\/10.3390\/medicina62061117","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]}}}